Compare Asana Inc. (ASAN) vs BioNano Genomics Inc (BNGO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Asana Inc. vs BioNano Genomics Inc — how do they compare? Asana Inc. trades at $9.16 (market cap $2.13B), while BioNano Genomics Inc trades at $1.18 (market cap $13.66M). The key difference: Asana Inc. is far larger — about 155.9× BioNano Genomics Inc's market cap, and Asana Inc. is trading nearer its 52-week high, BioNano Genomics Inc nearer its low. Which is the better fit depends on your goals.
| ASAN | BNGO | |
|---|---|---|
Market Cap | $2.13B | $13.66M |
Sector | Consumer Cyclical | Health |
52-Week High | $15.19 | $4.92 |
52-Week Low | $5.46 | $1.06 |
Enterprise Value | $1.96B | $16.26M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Asana (ASAN) trades at $9.065, down 1.79% on the day, with a bullish technical signal from moving averages but overbought RSI readings. Revenue growth is strong, reaching $723.88M in 2025, yet the company remains unprofitable with a net income margin of -20.21%. Recent earnings beats and AI product developments, including the StackAI acquisition, highlight operational momentum amid competitive pressures.
The outlook is mixed: analyst consensus leans neutral with a $10.33 price target, suggesting modest upside, but persistent losses and high valuation ratios pose risks. Key catalysts include continued AI integration and FedRAMP authorization, while decelerating revenue growth and competition from tech giants remain headwinds for shareholder value.
BNGO trades at $1.195, up 3.02% today, with a bullish technical signal from moving averages but a neutral oscillator stance. The company shows improving financial trends, with net losses narrowing to -$26.40M in 2025 from -$232M in 2023, and recent earnings beats. Revenue stabilized around $29M, while cash flow trends indicate reduced operational cash burn. Analyst sentiment is positive, with 57% buy ratings.
The outlook for BNGO hinges on sustaining revenue growth and achieving profitability, supported by strategic hires and debt retirement. Key risks include persistent negative margins and high cash burn. With a low P/S of 0.31, the stock offers value if execution improves, but investors face volatility from operational challenges and competitive pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Asana Inc.
Asana Inc is a software company. The company provides a platform for work management that helps teams orchestrate work, from daily tasks to cross-functional strategic initiatives. It helps plan marketing campaigns, streamlines processes, manages sales, and manage product launches. Also, the company provides project management and workflow management solutions.
Read more on ASAN →About BioNano Genomics Inc
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes.
Read more on BNGO →
